Marianne De Backer compensation by year
Vir Biotechnology Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $950,000 |
| Bonus | $0 |
| Stock awards | $2,296,800 |
| Option awards | $3,507,360 |
| Non-equity incentive | $1,002,750 |
| Pension and deferred compensation | $0 |
| All other | $77,135 |
| Total | $7,834,045 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vir Biotechnology, Inc. DEF 14A filed April 16, 2026, accession 0001628280-26-025379, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Vir Biotechnology, Inc. filed document, accession 0001628280-26-025379. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 288,226 | $1,738,003 | — |
| RSU | 240,000 | $1,447,200 | — |
| RSU | 131,250 | $791,438 | — |
| Option | 480,000 | — | $9.57 |
| Option | 189,584 | — | $10.11 |
| Option | 384,302 | — | $23.28 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vir Biotechnology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2025 proxy (filed April 16, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-29 | Other | — | 233,532 | $0.00 | 286,650 |
| 2026-04-29 | Other | — | 233,532 | $0.00 | 714,613 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Vir Biotechnology’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Marianne De Backer · this page | President, Chief Executive Officer and Director | $7,834,045 |
| Mark Eisner | Executive Vice President and Chief Medical Officer | $2,371,484 |
| Jason O'Byrne | Executive Vice President and Chief Financial Officer | $1,951,828 |
| Vanina de Verneuil | Executive Vice President, General Counsel and Corporate Secretary | $1,690,784 |
Board service
Vir Biotechnology board · FY2023–FY2025How this board is paid
Company policy: Vir Biotechnology pays directors a $50,000 cash retainer and $385,000 in Options and RSUs. As stated in Vir Biotechnology's FY2025 proxy.
Committees
Nominating/Governance
The full Vir Biotechnology compensation record
free company briefThis page is one person within Vir Biotechnology's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Vir Biotechnology proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Vir Biotechnology's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vir Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order VIR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.